 SAN DIEGO, Aug. 17, 2021 GLOBE NEWSWIRE -- AnaptysBio, Inc. Nasdaq: ANAB, a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that the U.S. Food and Drug Administration FDA approved a second indication for GSKs JEMPERLI dostarlimab-gxly for the treatment of adult patients with mismatch repair deficient dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. 